Kadmon Investors and Media

Investors

Press Releases

Press Releases

Kadmon Doses First Patient in Phase 1 Clinical Trial of KD033, an Anti-PD-L1/IL-15 Fusion Protein, in Adults with Metastatic or Locally Advanced Solid Tumors

NEW YORK, NY / ACCESSWIRE / June 23, 2020 /   Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating KD033, an anti-PD-L1/IL-15 fusion protein, in patients with metastatic or locally advanced solid tumors.... Read More

Kadmon to Present at the Raymond James 2020 Virtual Human Health Innovation Conference

NEW YORK, NY / ACCESSWIRE / June 11, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that Harlan W. Waksal , M.D., President and Chief Executive Officer, will present at the Raymond James 2020 Virtual Human Health Innovation Conference on Thursday, June 18, 2020 at 1:00 p.m. ET .... Read More

Kadmon Raises $50 Million in Gross Proceeds Through Its at-the-Market Facility

NEW YORK, NY / ACCESSWIRE / June 5, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that it has raised gross proceeds of $50.0 million through its At-The-Market (ATM) facility, including participation based on interest received from existing shareholders and new healthcare specialist... Read More

Kadmon to Present at the Jefferies 2020 Virtual Global Healthcare Conference

NEW YORK, NY / ACCESSWIRE / May 27, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that Harlan W. Waksal , M.D., President and Chief Executive Officer, will present at the Jefferies 2020 Virtual Global Healthcare Conference on Thursday, June 4, 2020 at 4:00 p.m. ET .... Read More

Kadmon Announces Positive Topline Results of Pivotal Trial of Belumosudil (KD025) in Chronic Graft-Versus-Host Disease

ORRs of 73% and 74% with Belumosudil (KD025) 200 mg QD and 200 mg BID, Respectively Kadmon Participating in FDA's Real-Time Oncology Review Pilot Program Conference Call Today at 8:30 a.m. Eastern Time NEW YORK, NY / ACCESSWIRE / May 21, 2020 / Kadmon Holdings, Inc.... Read More

Kadmon Provides Business Update and Reports First Quarter 2020 Financial Results

NEW YORK, NY / ACCESSWIRE / May 7, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today provided a business update and reported financial and operational results for the first quarter of 2020. "We made encouraging progress this past quarter, having completed our pre-NDA meeting with the FDA.... Read More

Kadmon Announces Receipt of Final Meeting Minutes from FDA Following Pre-NDA Meeting for KD025 for the Treatment of cGVHD

- Kadmon on Track for NDA Submission for KD025 in Q4 2020 - - Company to Announce Top-line Results from Primary Analysis in Q2 2020 - NEW YORK, NY / ACCESSWIRE / April 14, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that it has received the final meeting minutes from the U.S.... Read More

Kadmon Announces Update on pre-NDA Meeting with FDA and Provides Business Update

NEW YORK, NY / ACCESSWIRE / March 13, 2020 / Kadmon Holdings, Inc. (NYSE: KDMN) today announced that the Company held its pre-New Drug Application (NDA) meeting as scheduled with the U.S. Food and Drug Administration (FDA) for KD025 for the treatment of patients with chronic graft-versus-host... Read More

Kadmon Highlights Recent Progress and Reports Fourth Quarter and Full Year 2019 Financial Results

NEW YORK, March 05, 2020 (GLOBE NEWSWIRE) -- Kadmon Holdings, Inc. (NYSE: KDMN) today provided a business update and reported financial and operational results for the fourth quarter and full year ended December 31, 2019. “We achieved significant progress in 2019, led by positive results from the... Read More

Kadmon Announces Expanded Results of Interim Analysis of Pivotal Trial of KD025 in cGVHD

Patient Analyses and Safety Data Continue to Underscore Positive Impact of KD025 in cGVHD Pre-NDA Meeting with FDA Planned for March 2020 ; Topline Results of Primary Analysis to be Announced in Q2 2020 NEW YORK, NY / ACCESSWIRE / February 23, 2020 / Kadmon Holdings, Inc.... Read More
Displaying 1 - 10 of 11